Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Primary Myelofibrosis 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Waldenstrom Macroglobulinemia 1Sarcoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 87fludarabine phosphate 86Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 58Tacrolimus 57Busulfan 57Whole-Body Irradiation 55Antilymphocyte Serum 47Cyclosporine 46fludarabine 39Methotrexate 38Filgrastim 38Melphalan 32ruxolitinib 30Cytarabine 30Radiotherapy 27Azacitidine 23Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Specimen Handling 15Sirolimus 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Biopsy 15Flow Cytometry 14Cyclosporins 14Alemtuzumab 14thymoglobulin 13venetoclax 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × selinexor × Myeloid × Clear all
NCT07626021 2026-06-04

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

Zhongshan Hospital (Xiamen), Fudan University

Phase 2 Not yet recruiting
15 enrolled
Myeloid

Myeloproliferative Disorders

NCT04562389 2026-04-09

SENTRY

Karyopharm Therapeutics Inc

Phase 3 Active not recruiting
353 enrolled
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡